Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Innoviva Inc (INVA)

Innoviva Inc (INVA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,526,274
  • Shares Outstanding, K 101,279
  • Annual Sales, $ 261,020 K
  • Annual Income, $ 157,290 K
  • 60-Month Beta 1.42
  • Price/Sales 5.80
  • Price/Cash Flow 3.63
  • Price/Book 4.43

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Sell
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate 0.36
  • Number of Estimates 1
  • High Estimate 0.36
  • Low Estimate 0.36
  • Prior Year 0.31
  • Growth Rate Est. (year over year) +16.13%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.72 +9.84%
on 01/31/20
15.19 -0.82%
on 02/12/20
+0.92 (+6.50%)
since 01/14/20
3-Month
12.24 +23.12%
on 11/15/19
15.19 -0.82%
on 02/12/20
+2.88 (+23.63%)
since 11/14/19
52-Week
10.03 +50.25%
on 09/26/19
16.29 -7.49%
on 02/27/19
+0.34 (+2.31%)
since 02/14/19

Most Recent Stories

More News
Armata Pharmaceuticals Announces Closing of First Tranche of Recently Executed $25 Million Securities Purchase Agreement with Innoviva, Inc.

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today...

INVA : 15.07 (+0.80%)
Innoviva: 4Q Earnings Snapshot

BURLINGAME, Calif. (AP) _ Innoviva Inc. (INVA) on Wednesday reported fourth-quarter earnings of $45.9 million.

INVA : 15.07 (+0.80%)
Innoviva Reports Fourth Quarter 2019 Financial Results

Innoviva, Inc. (NASDAQ: INVA) (the Company) today reported financial results for the fourth quarter ended December 31, 2019.

INVA : 15.07 (+0.80%)
What's in Store for Innoviva (INVA) This Earnings Season?

Strong demand for Glaxo's Trelegy Ellipta is likely to have driven royalties for Innoviva (INVA) in the fourth quarter, which is partially offset by lower royalties from Relvar/Breo Ellipta.

GSK : 43.74 (-0.09%)
HZNP : 35.93 (+0.25%)
REGN : 399.55 (+0.19%)
INVA : 15.07 (+0.80%)
Armata Pharmaceuticals and Innoviva Announce $25 Million Strategic Investment to Support Advancement of Armata's Bacteriophage Development Programs

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, and Innoviva, Inc. (NASDAQ:...

INVA : 15.07 (+0.80%)
Noteworthy Monday Option Activity: INVA, R, NVTA

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Innoviva Inc , where a total of 4,287 contracts have traded so far, representing approximately...

INVA : 15.07 (+0.80%)
Innoviva (INVA) Outpaces Stock Market Gains: What You Should Know

Innoviva (INVA) closed at $13.91 in the latest trading session, marking a +0.87% move from the prior day.

INVA : 15.07 (+0.80%)
Jazz Enrolls First Patient in Phase II/III Leukemia Study

Jazz (JAZZ) begins enrollment in the phase II/III study evaluating JZP-458 for treating pediatric and adult patients with acute lymphoblastic leukemia, hypersensitive to E. coli-derived asparaginases

INVA : 15.07 (+0.80%)
JAZZ : 140.85 (-0.76%)
ACRX : 1.60 (-4.19%)
GH : 84.30 (+3.06%)
Acceleron, Fulcrum Therapeutics Ink Deal for Pulmonary Disease

Acceleron (XLRN) signs a collaboration/license pact with Fulcrum Therapeutics aimed at identifying small molecules designed to modulate specific pathways targeting a pulmonary disease indication.

XLRN : 93.66 (-0.48%)
INVA : 15.07 (+0.80%)
FULC : 15.20 (+1.60%)
GH : 84.30 (+3.06%)
BeiGene Gets Approval for Lymphoma Drug Tislelizumab in China

BeiGene's (BGNE) tislelizumab gets an NMPA nod in China for treating patients with classical Hodgkin's lymphoma, having received minimum two prior therapies.

BMY : 66.38 (+0.45%)
BGNE : 171.09 (+1.57%)
INVA : 15.07 (+0.80%)
GH : 84.30 (+3.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade INVA with:

Business Summary

Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance,...

See More

Key Turning Points

2nd Resistance Point 15.34
1st Resistance Point 15.20
Last Price 15.07
1st Support Level 14.92
2nd Support Level 14.78

See More

52-Week High 16.29
Last Price 15.07
Fibonacci 61.8% 13.90
Fibonacci 50% 13.16
Fibonacci 38.2% 12.42
52-Week Low 10.03

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar